MJP Associates Inc. ADV Buys 1,613 Shares of Novo Nordisk A/S $NVO

MJP Associates Inc. ADV grew its stake in Novo Nordisk A/S (NYSE:NVO) by 44.1% in the second quarter, HoldingsChannel.com reports. The fund owned 5,271 shares of the company’s stock after acquiring an additional 1,613 shares during the period. MJP Associates Inc. ADV’s holdings in Novo Nordisk A/S were worth $364,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. Xponance Inc. lifted its holdings in Novo Nordisk A/S by 5.0% during the first quarter. Xponance Inc. now owns 3,314 shares of the company’s stock worth $230,000 after acquiring an additional 158 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Novo Nordisk A/S by 40.9% in the first quarter. Massachusetts Financial Services Co. MA now owns 141,053 shares of the company’s stock worth $9,795,000 after acquiring an additional 40,945 shares in the last quarter. Bailard Inc. raised its position in shares of Novo Nordisk A/S by 49.3% during the first quarter. Bailard Inc. now owns 12,968 shares of the company’s stock worth $900,000 after purchasing an additional 4,282 shares during the period. Finally, Kingsview Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 9.3% during the 1st quarter. Kingsview Wealth Management LLC now owns 5,404 shares of the company’s stock valued at $375,000 after purchasing an additional 461 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NVO. Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. BMO Capital Markets reissued a “market perform” rating and issued a $55.00 price target (up previously from $50.00) on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. Finally, Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Stock Down 1.9%

NYSE:NVO opened at $48.22 on Friday. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $112.52. The firm has a market capitalization of $215.32 billion, a price-to-earnings ratio of 13.25, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock’s 50 day moving average price is $54.55 and its two-hundred day moving average price is $61.01.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.74 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.